Effect of PD-1 Immunosuppressant Combined with Chemotherapy in Treating Advanced NSCLC and Its Influence on Tumor Markers and Prognosis
Objective:To explore the effect of PD-1 immunosuppressant combined with chemotherapy in the treatment of advanced non-small cell lung cancer(NSCLC)and its influence on tumor markers and prognosis.Methods:Patients with stage Ⅲ-B-ⅣNSCLC admitted from June 2020 to June 2023 were retrospectively selected as the study subjects,and were divided into chemotherapy group(n=32,pemetrexed/paclitaxel+platinum chemotherapy regimen)and combined group(n=36,camrelizumab+pemetrexed/paclitaxel+platinum chemotherapy regimen).The solid tumor treatment effect[disease control rate(DCR),objective response rate(ORR)]and follow-up prognosis and survival[progression-free survival(PFS),overall survival(OS)]after at least 2 cycles of treatment,adverse drug reactions during treatment and levels of serum biochemical indicators[carcinoembryonic antigen(CEA),cytokeratin 19 fragment antigen(CY-FRA21-1),albumin(ALB)]before treatment and after 2 cycles of treatment were compared between both groups.Results:After 2 cycles of treatment,DCR in combined group was significantly higher than that in chemotherapy group(83.33％vs 59.38％)(P＜0.05),but ORR was not significantly different from that in chemotherapy group(58.33％vs 40.63％)(P＞0.05).After 18 months of follow-up,the PFS,the number of dead cases and OS in combined group were(11.44±1.81)months,11 cases and(15.17± 1.42)months and those in chemotherapy group were(6.87±3.05)months,16 cases and(11.91±1.09)months.The PFS was significantly longer in combined group than that in chemotherapy group(log rank x2=4.377,P＜0.05),but there was no significant difference in OS between the two groups(log rank x2=3.442,P＞0.05).During treatment,the total incidence rate of adverse drug reactions showed no significant difference between the two groups(P＞0.05).After 2 cycles of treatment,the levels of CEA and CY-FRA21-1 in both groups were gradually reduced(P＜0.05)while the level of ALB was significantly risen(P＜0.05),and the changes of the above indic()s in combined group were significantly higher compared to chemotherapy group(P＜0.05).Conclusion:PD-1 immunosuppressant combined with chemotherapy is effective in the treatment of advanced NSCLC,which can significantly inhibit the tumor progression,prolong the PFS,and improve the prognosis.
NETL
NSTL
万方数据
